Inhibitors of multidrug efflux transporters: their membrane and protein interactions.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2005-01-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/1389557053402693PMID 15720284
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changes in membrane microdomains and caveolae constituents in multidrug-resistant cancer cells

  2007cited by this paper
• Pharmacologic circumvention of multidrug resistance

  2004cited by this paper
• Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells

  2003cited by this paper
• Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier.

  2003cited by this paper
• The role of surfactants in the reversal of active transport mediated by multidrug resistance proteins.

  2003cited by this paper
• Compound Profiling for P-Glycoprotein at the Blood–Brain Barrier Using a Microplate Screening System

  2003cited by this paper
• Considerations in the design and development of transport inhibitors as adjuncts to drug therapy.

  2003cited by this paper
• Inhibitory effect of fruit extracts on P‐glycoproteinrelated efflux carriers: an in‐vitro screening

  2002cited by this paper
• Progress in understanding the structure-activity relationships of P-glycoprotein.

  2002cited by this paper
• Real-time monitoring of P-glycoprotein activation in living cells.

  2002cited by this paper
• Mammalian ABC transporters in health and disease.

  2002cited by this paper
• Multidrug resistance in cancer: role of ATP–dependent transporters

  2002cited by this paper
• Drug transport across the blood-brain barrier.

  2002cited by this paper
• Inhibitors of multidrug resistance to antitumor agents (MDR).

  2002cited by this paper
• Genomics and the prediction of xenobiotic toxicity.

  2002cited by this paper
• Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein.

  2002cited by this paper
• Fungal ABC proteins: pleiotropic drug resistance, stress response and cellular detoxification.

  2001cited by this paper
• In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

  2001cited by this paper
• From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance

  2001cited by this paper
• P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.

  2001cited by this paper
• Characterization of the Catalytic Cycle of ATP Hydrolysis by Human P-glycoprotein

  2001cited by this paper
• Quantitative distinctions of active site molecular recognition by P-glycoprotein and cytochrome P450 3A4.

  2001cited by this paper
• Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes

  2001cited by this paper
• Drug transport by reconstituted P-glycoprotein in proteoliposomes. Effect of substrates and modulators, and dependence on bilayer phase state.

  2001cited by this paper
• Overview: ABC Transporters and Human Disease

  2001cited by this paper
• Antibiotic efflux pumps.

  2000cited by this paper
• Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats

  2000cited by this paper
• Communication between multiple drug binding sites on P-glycoprotein.

  2000cited by this paper
• Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.

  2000cited by this paper
• Plant ABC transporters.

  2000cited by this paper
• Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).

  2000cited by this paper
• Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs.

  2000cited by this paper
• The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

  2000cited by this paper
• Molecular Properties of Bacterial Multidrug Transporters

  2000cited by this paper
• Lipid Traffic: The ABC of Transbilayer Movement

  2000cited by this paper
• Structure-activity relationship of P-glycoprotein substrates and modifiers.

  2000cited by this paper
• P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs.

  2000cited by this paper
• Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison.

  2000cited by this paper
• Influence of Passive Permeability on Apparent P-glycoprotein Kinetics

  2000cited by this paper
• Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.

  1999cited by this paper
• Uncoupled Active Transport Mechanisms Accounting for Low Selectivity in Multidrug Carriers: P-Glycoprotein and SMR Antiporters

  1999cited by this paper
• Energy-dependent efflux from Leishmania promastigotes of substrates of the mammalian multidrug resistance pumps.

  1999cited by this paper
• Biochemical, cellular, and pharmacological aspects of the multidrug transporter.

  1999cited by this paper
• A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel

  1999cited by this paper
• Diltiazem Increases Tacrolimus Concentrations

  1999cited by this paper
• Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives.

  1999cited by this paper
• ABC-ATPases, adaptable energy generators fuelling transmembrane movement of a variety of molecules in organisms from bacteria to humans.

  1999cited by this paper
• The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporter.

  1999cited by this paper
• Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein.

  1998cited by this paper
• A general pattern for substrate recognition by P-glycoprotein.

  1998cited by this paper
• Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP.

  1998cited by this paper
• Stoichiometry of coupling of rhodamine 123 transport to ATP hydrolysis by P-glycoprotein.

  1998cited by this paper
• Blood-Brain Barrier Permeation: Molecular Parameters Governing Passive Diffusion

  1998cited by this paper
• Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.

  1998cited by this paper
• From ab initio quantum mechanics to molecular neurobiology: a cation-pi binding site in the nicotinic receptor.

  1998cited by this paper
• N‐Dealkylation of Chlorimipramine and Chlorpromazine by Rat Liver Microsomal Cytochrome P450 Isoenzymes

  1998cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by XR9051, a novel diketopiperazine derivative.

  1998cited by this paper
• Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP.

  1997cited by this paper
• Kinetics of the multidrug transporter (P-glycoprotein) and its reversal.

  1997cited by this paper
• Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes.

  1997cited by this paper
• Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity.

  1997cited by this paper
• Functional modulation of ATPase of P-glycoprotein by C219, a monoclonal antibody against P-glycoprotein.

  1997cited by this paper
• Search for specific inhibitors of multidrug resistance in cancer.

  1997cited by this paper
• ATPase activity of P-glycoprotein related to emergence of drug resistance in Ehrlich ascites tumor cell lines.

  1997cited by this paper
• Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.

  1997cited by this paper
• Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein.

  1997cited by this paper
• Extraction of Hoechst 33342 from the cytoplasmic leaflet of the plasma membrane by P-glycoprotein.

  1997cited by this paper
• Competitive, non-competitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity.

  1997cited by this paper
• The functional purification of P-glycoprotein is dependent on maintenance of a lipid-protein interface.

  1997cited by this paper
• Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.

  1996cited by this paper
• Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979.

  1996cited by this paper
• Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells.

  1996cited by this paper
• Functional Reconstitution of P-glycoprotein Reveals an Apparent Near Stoichiometric Drug Transport to ATP Hydrolysis (*)

  1996cited by this paper
• Comparative in vitro evaluation of dithiane analogs of tiapamil, Ro 11-2933, Ro 44-5911 and Ro 44-5912 as multidrug resistance modulators

  1996cited by this paper
• Chlorpromazine transport in membrane vesicles from multidrug resistant CCRF‐CEM cells

  1996cited by this paper
• Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans

  1995cited by this paper
• Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy

  1995cited by this paper
• RS-33295-198: a novel, potent modulator of P-glycoprotein-mediated multidrug resistance.

  1995cited by this paper
• MDR1 Gene Expression in Brain of Patients with Medically Intractable Epilepsy

  1995cited by this paper
• Reversal of multidrug resistance by a novel quinoline derivative, MS-209

  1995cited by this paper
• Phase I/II trial of dexverapamil plus vinblastine for patients with advanced renal cell carcinoma.

  1995cited by this paper
• New mechanisms of drug resistance in parasitic protozoa.

  1995cited by this paper
• Structure-activity relationship of verapamil analogs and reversal of multidrug resistance.

  1995cited by this paper
• P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

  1995cited by this paper
• Mechanism of action of dexniguldipine-HCl (B8509-035), a new potent modulator of multidrug resistance.

  1995cited by this paper
• MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

  1995cited by this paper
• Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole.

  1994cited by this paper
• A method to determine the ability of drugs to diffuse through the blood-brain barrier.

  1994cited by this paper
• Effect of monolayer surface pressure on the activities of phosphoinositide-specific phospholipase C-beta 1, -gamma 1, and -delta 1.

  1994cited by this paper
• Covalent inhibitors of P-glycoprotein ATPase activity.

  1994cited by this paper
• Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation.

  1993cited by this paper
• Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein.

  1993cited by this paper
• In vitro and in vivo reversal of multidrug resistance by GF120918, an acridonecarboxamide derivative.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.

  1993cited by this paper
• Characterization of the P-glycoprotein over-expressing drug resistance phenotype exhibited by Chinese hamster ovary cells following their in-vitro exposure to fractionated X-irradiation.

  1993cited by this paper
• P‐glycoprotein‐mediated transcellular transport of MDR‐reversing agents

  1993cited by this paper
• The cytosensor microphysiometer: biological applications of silicon technology.

  1992cited by this paper
• Is the multidrug transporter a flippase?

  1992cited by this paper
• In vitro andin vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative

  1992cited by this paper

• Trends in Molecular Properties, Bioavailability, and Permeability across the Bayer Compound Collection.

  2023cites this paper
• The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects

  2023cites this paper
• Recent advances in peptide-based therapeutic strategies for breast cancer treatment

  2023cites this paper
• [(WR)8WKβA]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin

  2022cites this paper
• Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity.

  2021cites this paper
• Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.

  2019cites this paper
• EMERGING TRENDS IN ORAL BIOAVAILABILITY ENHANCEMENT

  2018cites this paper
• Temperature dependent solvation in phospholipid membranes

  2017cites this paper
• Quantifying Solute Partitioning in Phosphatidylcholine Membranes.

  2017cites this paper
• ABCG2/BCRP: Specific and Nonspecific Modulators

  2017cites this paper
• P-gp Inhibitors: A Potential Tool to Overcome Drug Resistance in Cancer Chemotherapy

  2016cites this paper
• Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

  2016cites this paper
• P-glikoprotein ve Tedaviye Dirençteki Rolü

  2016cites this paper
• Predicting Activators and Inhibitors of the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1) Based on Mechanistic Considerations.

  2015cites this paper
• Allocrite Sensing and Binding by the Breast Cancer Resistance Protein (ABCG2) and P-Glycoprotein (ABCB1).

  2015cites this paper
• P-glikoprotein ve Tedaviye Dirençteki Rolü P-glycoprotein and its Role in Treatment Resistance

  2015cites this paper
• Chapter 14 – Drugs That Modulate Resistance to Antitumor Agents

  2015cites this paper
• Selenorhodamine Photosensitizers for Photodynamic Therapy of P-Glycoprotein-Expressing Cancer Cells

  2014cites this paper
• Structure-Based Prediction of Drug Distribution Across the Headgroup and Core Strata of a Phospholipid Bilayer Using Surrogate Phases

  2014cites this paper
• Physiological modulation approaches to improve cancer chemotherapy : a review.

  2014cites this paper
• The inhibition of ABC transporters in cancer multidrug resistance by heterocyclic cyclohexanone analogues of curcumin

  2014cites this paper
• Structural Determinants of Drug Partitioning in n-Hexadecane/Water System

  2013cites this paper
• Prioritisation of organic contaminants in a river basin using chemical analyses and bioassays

  2013cites this paper
• Cyclic peptides: Design, characterization, self-assembly, and applications as nano drug delivery systems

  2013cites this paper
• Fluorescent substrates for flow cytometric evaluation of efflux inhibition in ABCB1, ABCC1, and ABCG2 transporters.

  2013cites this paper
• Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs.

  2013cites this paper
• Structural determinants of drug partitioning in surrogates of phosphatidylcholine bilayer strata.

  2013cites this paper
• Thiorhodamines containing amide and thioamide functionality as inhibitors of the ATP-binding cassette drug transporter P-glycoprotein (ABCB1).

  2012cites this paper
• The influence of mass of [11C]-laniquidar and [11C]-N-desmethyl-loperamide on P-glycoprotein blockage at the blood-brain barrier.

  2012cites this paper
• Synthesis of benzo- and naphtho-fused bicyclo[n.3.1]alkane frameworks with a bridgehead nitrogen function by palladium-catalyzed intramolecular α'-arylation of α-nitroketones.

  2011cites this paper
• The multidrug transporter Pdr5: a molecular diode?

  2011cites this paper
• MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.

  2011cites this paper
• Immunosuppressors as multidrug resistance reversal agents.

  2010cites this paper
• P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity.

  2010cites this paper
• Detergents as intrinsic P-glycoprotein substrates and inhibitors.

  2009cites this paper
• Modeling Kinetics of Subcellular Disposition of Chemicals

  2009cites this paper
• QSAR analysis and molecular modeling of ABCG2-specific inhibitors.

  2009cites this paper
• Design of new drug molecules to be used in reversing multidrug resistance in cancer cells.

  2009cites this paper
• Rhodamine inhibitors of P-glycoprotein: an amide/thioamide "switch" for ATPase activity.

  2009cites this paper
• QSAR Studies on ABC Transporter – How to Deal with Polyspecificity

  2009cites this paper
• Reversal Agents for P‐Glycoprotein‐Mediated Multidrug Resistance

  2009cites this paper
• Multidrug resistance through the spectacle of P-glycoprotein.

  2009cites this paper
• Multidrug resistance reverting activity and antitumor profile of new phenothiazine derivatives.

  2008cites this paper
• P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle.

  2008cites this paper
• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  2008cites this paper
• Chalcogenopyrylium dyes as inhibitors/modulators of P-glycoprotein in multidrug-resistant cells.

  2008cites this paper
• Synthesis and biological evaluation of (hetero)arylmethyloxy- and arylmethylamine-phenyl derivatives as potent P-glycoprotein modulating agents.

  2008cites this paper
• ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling.

  2008cites this paper
• Toward Understanding P‐Glycoprotein Structure–Activity Relationships

  2008cites this paper
• Drugs That Modulate Resistance to Antitumor Agents

  2008cites this paper
• "In silico" prediction of blood-brain barrier permeation and P-glycoprotein activity

  2008cites this paper
• A multi-factorial approach to understanding and predicting brain exposure to pharmacologic agents

  2008cites this paper
• Chemotherapy-induced resistance by ATP-binding cassette transporter genes.

  2007cites this paper
• The role of the lipid membrane for the function of the ABC transporter P-glycoprotein

  2007cites this paper
• The Role of Size and Charge for Blood–Brain Barrier Permeation of Drugs and Fatty Acids

  2007cites this paper
• P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells.

  2007cites this paper
• Contrasting features of MDR phenotype in leukemias by using two fluorochromes: implications for clinical practice.

  2007cites this paper
• Interaction of verapamil with lipid membranes and P-glycoprotein: connecting thermodynamics and membrane structure with functional activity.

  2006cites this paper
• In Silico Prediction of Blood-Brain Barrier Permeation Using the Calculated Molecular Cross-Sectional Area as Main Parameter

  2006cites this paper
• P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites.

  2006cites this paper
• New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity.

  2006cites this paper
• Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding

  2006influential citation
• Quantification and characterization of P-glycoprotein-substrate interactions.

  2006cites this paper
• New potent P-glycoprotein inhibitors carrying a polycyclic scaffold.

  2006cites this paper
• Pharmacokinetic interactions affecting the antidiabetic repaglinide

  2006cites this paper
• Stimulation of P-glycoprotein ATPase by analogues of tetramethylrosamine: coupling of drug binding at the "R" site to the ATP hydrolysis transition state.

  2006cites this paper
• Interaction of transported drugs with the lipid bilayer and P-glycoprotein through a solvation exchange mechanism.

  2006cites this paper
• Unraveling membrane-mediated substrate-transporter interactions.

  2006cites this paper
• P-glycoprotein recognition of substrates and circumvention through rational drug design.

  2006cites this paper
• Targeting multidrug resistance in cancer

  2006cites this paper
• A cationic chalcogenoxanthylium photosensitizer effective in vitro in chemosensitive and multidrug-resistant cells.

  2006cites this paper
• Which in vitro screens guide the prediction of oral absorption and volume of distribution

  2005cites this paper
• The Steady-State Michaelis–Menten Analysis of P-Glycoprotein Mediated Transport Through a Confluent Cell Monolayer Cannot Predict the Correct Michaelis Constant Km

  2005cites this paper
• The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells.

  2005cites this paper
• Synthesis of doxorubicin-peptide conjugate with multidrug resistant tumor cell killing activity.

  2005cites this paper
• The rate of P-glycoprotein activation depends on the metabolic state of the cell.

  2004cites this paper